Physician profile
Edward Robert Kost
NPI 1184615452
$5,593.11
in general payments reported to CMS, 2019-2025
10 companies · $141 in 2025
The $141 reported for 2025 was less than what a typical Gynecologic Oncology provider received nationally (typical 2025 total: $305).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $118 · 2021: $2,203 · 2022: $408 · 2023: $691 · 2024: $2,032 · 2025: $141.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $1,715 · Food and Beverage: $1,149.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $1,715.00 |
| Food and Beverage | $1,148.61 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $2,207.92 | 2021-2024 | Lynparza |
| Glaxosmithkline, LLC. | $1,950.00 | 2021 | |
| Seagen INC. | $477.87 | 2021-2023 | Tivdak |
| Myriad Genetic Laboratories, INC. | $288.56 | 2022-2024 | Mychoice Cdx |
| Immunogen, INC. | $273.70 | 2023 | Elahere |
| Merck Sharp & Dohme LLC | $124.99 | 2025 | Keytruda |
| Eisai INC. | $122.56 | 2023 | |
| Clovis Oncology, INC. | $118.26 | 2019 | |
| Corcept Therapeutics | $15.91 | 2025 | Korlym |
| Therapeuticsmd, INC. | $13.34 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Edward Kost listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.